The Ingredient Tab Is Where the Claim Gets Made

which ingredient-glossary text did FDA quote back at Anna Health?

FDA quoted an ingredient glossary, not the sales headline, when it warned Anna Health, LLC on March 16, 2021 (CMS 613294). The warning letter to Anna Health pulls this line straight from the site's "Main Ingredients" tab: "Serenoa Repens (Saw palmetto) …treatment of benign prostatic hyperplasia (BPH)…reduces urinary problems…useful with prostate cancer." Nobody wrote that sentence to sell anything — it reads like a monograph. FDA cited it anyway.

The ingredient tab was cited on top of those, not instead of them.

The dividing line, covered in Structure/Function vs Disease Claims in Supplement Ads, is simple to state: a structure/function claim, a claim about normal body function, needs no disease reference at all. Every quoted line above names one, BPH or prostate cancer, which is what converted a bottle of saw palmetto into an unapproved drug.

• "Improves…urinary flow."
• "Relieves symptoms of BPH (Enlarged Prostate)."
• "Protects against prostate cancer."
• "Reduces urinary urgency."

why did calling the condition 'a normal part of a man's aging process' still get cited?

Because naming a disease doesn't stop being a disease claim just because the sentence calls it normal. FDA's warning letter to Natural Hope Herbals, LLC, dated June 10, 2021 (CMS 612467), cited exactly one sentence from the "Prostate Health" product page: "Decreased prostate function (benign prostate hypertrophy) is a normal part of a man's aging process." The sentence argues the opposite of alarm. FDA cited it anyway, because it names BPH by its clinical name inside the argument.

Calling a disease natural does not make it stop being a disease.

FDA drew this line deliberately in its 2000 rule. The preamble to 65 FR 1000 excludes BPH from its list of conditions treated as ordinary aging, reasoning that even a condition tied to aging still counts as disease because failure to get effective treatment can cause lasting harm. The safe harbor that partly rescues erectile-dysfunction copy for men targeting age-related decline was never available here.

how did a hair-loss product become an unapproved prostate drug claim?

A DHT explainer pulled prostate disease into a hair-loss page that never tried to sell prostate health. FDA's April 7, 2026 letter to Nature's Elements, Inc. (CMS 719302) cites the "DHT Blocker" product page for a benefit line naming prostate directly, and separately for the mechanism paragraph explaining how the ingredient works: "Extra DHT levels can cause prostate problems in men like enlarged prostate and BHP [sic] problems which left untreated can lead to sexual dysfunction." DHT, a hormone linked to hair loss, is also linked here to a named disease.

FDA found three separate violations on the same page: unapproved new drug, a product not cleared for that use; misbranded, meaning its labeling itself breaks the law; and adulterated, meaning production violated manufacturing rules under CGMP, FDA's quality rulebook, found during inspection. Sales copy never had to mention prostate for the claim to land; explaining the mechanism did that on its own.

what makes the mechanism explanation itself the riskiest block on an advertorial?

Explaining how an ingredient works is what most often drags disease language into an advertorial, an ad styled like an article, when the sales copy above it avoided it entirely. Prostate creatives standardly run a DHT or 5-alpha-reductase, the enzyme that produces DHT, villain story: an enzyme converts testosterone into a compound that enlarges the prostate, and the ingredient supposedly blocks it, paired with a nocturia hook, getting up at night to urinate, because the symptom needs no diagnosis to be recognized. Both halves are legally hazardous on their own: the symptom hook names a characteristic sign of a named disease under 21 CFR 101.93(g)(2)(ii), and the mechanism paragraph is precisely the block FDA cited in the Nature's Elements letter. FDA's own rule permits a statement that characterizes a documented mechanism only when the statement is not itself a disease claim, so a more elaborate explanation increases exposure rather than reducing it.

A mechanism paragraph reads as educational to the writer and as a disease claim to FDA, and the record shows the agency reads it the second way.

why can a compliant headline sit on top of a non-compliant page?

Because ad and label review both examine the whole page, not the top of it. FTC's guidance defines advertising broadly enough to cover statements on packaging, in promotional brochures and in digital content, which folds ingredient tabs, FAQs and mechanism explainers into the same liability the headline carries. A landing page can lead with a clean, generic benefit statement and still fail on an accordion three scrolls down.

FDA's own claim rule works the same way. Under 21 CFR 101.93(g)(2), a disease claim can arrive through the product's name, its formulation statements, a cited publication, or "pictures, vignettes, symbols, or other means," none of which live in the headline.

which page furniture counts as labeling: accordions, FAQs, herb monographs, footnotes?

All of it. FDA's own list of disease-claim triggers doesn't distinguish supplement landing page ingredient claims by where they sit — headline, accordion, or footnote all count the same way. 21 CFR 101.93(g)(2)(iv) names the product's name, its formulation statements, cited publications and imagery as independent routes to a disease claim, a list written before landing-page accordions existed but broad enough to reach every one of them.

If you're deciding whether to show a full Supplement Facts panel on the page, the tradeoff runs the other way in Showing the Label: Does Ingredient Transparency Sell or Stall the Order? — but the ingredient tab is claim surface regardless of whether the panel itself is shown.

when does FDA say no rewrite could have cured the violation at all?

FDA says no rewrite works once a product's own claims make it intended to treat a disease that a layperson can't safely self-diagnose or self-treat. In the Anna Health letter, that finding led directly to this line: "it is impossible to write adequate directions for a layperson to use your products safely for their intended purposes." No dosage instruction, no added warning, no FAQ fixes that.

No label edit fixes a claim built to sell a disease.

The DSHEA disclaimer doesn't change this calculus; under 21 CFR 101.93(c) and (f), the required boilerplate only accompanies a lawful structure/function claim and never converts an unlawful one.

We checked FDA's own list of twelve authorized health claims and found none covering prostate, joints, veins or sleep, which is why the cholesterol claims FDA actually authorized is the rare exception where a supplement can point to a real regulated claim instead of leaning on structure/function alone.

what should a media buyer audit before pushing spend at an advertiser's page?

Read past the top headline before committing budget — the ingredient tab, FAQ accordion and any "how it works" block need the same scrutiny the headline gets. We read all three letters in this record against FDA's own ten-trigger list at 21 CFR 101.93(g)(2) and found the pattern holds across every format: name, image, footnote or glossary entry, each one counts on its own.

One thing we could not verify: whether a general prostate-health statement with no symptom, size or PSA reference would actually survive FDA review, since the agency has published no approved example and rejected the closest wording put in front of it. Only a future FDA warning letter, or a formal advisory opinion request, would settle that question one way or the other.

Other niches leave more open ground for this kind of general statement — see the calm claims FDA listed as acceptable for wording FDA has actually blessed — but prostate copy shouldn't borrow that comfort until its own version exists in writing.

• Does the headline, subhead, or product name reference a disease, a symptom, or a clinical abbreviation such as BPH?
• Does your ingredient tab, FAQ, or herb monograph mention a disease anywhere, even as reassurance?
• Does a "how it works" or mechanism block name a condition while it explains the science?
• Is a "normal aging" frame wrapped around a condition FDA has expressly excluded from that safe harbor, like BPH?
• Is the required disclaimer present, and does the copy sitting above it already contradict it?

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Herbal Prozac, Nature's Adderall: Substitute Claims, Why 'Results Not Typical' Stopped Protecting Ads, Your Money-Back Guarantee Wording Is a Claim, Anti-Aging's Floor: Alzheimer's, Osteoporosis, Glaucoma, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.